News
JAZZ
125.19
+1.18%
1.46
Carillon Chartwell Short Duration High Yield Fund Q3 2024 Commentary
Seeking Alpha · 13h ago
Sentiment Still Eluding Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
Simply Wall St · 1d ago
Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
Seeking Alpha · 3d ago
Weekly Report: what happened at JAZZ last week (1216-1220)?
Weekly Report · 3d ago
Executive reshuffles: BA, EXPE, TPVG and GEO
Seeking Alpha · 4d ago
Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule
Seeking Alpha · 12/19 14:00
Akari Therapeutics appoints Samir Patel as CEO
TipRanks · 12/18 14:01
Jazz Pharmaceuticals (JAZZ) Gets a Buy from TD Cowen
TipRanks · 12/17 12:15
Jazz Pharma CEO Bruce Cozadd To Retire
NASDAQ · 12/17 01:29
Jazz Pharmaceuticals Announces CEO Bruce Cozadd’s Retirement Plan
TipRanks · 12/16 21:57
Jazz Pharmaceuticals CEO Bruce Cozadd to retire by end of 2025
TipRanks · 12/16 21:11
Jazz Pharmaceuticals CEO to retire
Seeking Alpha · 12/16 21:10
Jazz Pharmaceuticals Announces CEO Succession Plan; Bruce Cozadd, Co-Founder, Chairperson And CEO, Plans To Retire As CEO Upon Appointment Of Successor By The End Of 2025; Will Continue As Chair Of The Board; Jazz Remains On Track To Meet Its FY24 Total Revenue Guidance Of Between $4B-$4.1B
Benzinga · 12/16 21:07
JAZZ PHARMACEUTICALS ANNOUNCES CEO SUCCESSION PLAN
Reuters · 12/16 21:05
JAZZ PHARMACEUTICALS OUTLOOK FY REVENUE USD 4,000-4,100 MILLION
Reuters · 12/16 21:05
JAZZ PHARMACEUTICALS PLC: BRUCE COZADD WILL CONTINUE AS CHAIR OF BOARD
Reuters · 12/16 21:05
Weekly Report: what happened at JAZZ last week (1209-1213)?
Weekly Report · 12/16 09:03
Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (JAZZ), Acadia Healthcare (ACHC) and Genmab (GMAB)
TipRanks · 12/16 06:01
Truist Financial Gives a Buy Rating to Jazz Pharmaceuticals (JAZZ)
TipRanks · 12/13 12:17
Jazz Pharmaceuticals Price Target Maintained With a $163.00/Share by Piper Sandler
Dow Jones · 12/12 18:06
More
Webull provides a variety of real-time JAZZ stock news. You can receive the latest news about Jazz Pharmaceuticals Plc through multiple platforms. This information may help you make smarter investment decisions.
About JAZZ
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).